Zenas Biopharma Inc ZBIO
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2024-09-13 |
| Shares Out. | 63,130,000 |
| Website | zenasbio.com/ ↗ |
| Phone | 18572712954 |
| Employees | 167 |
| Net Income | -$81.0M |
| Free Cash Flow | -$210.5M |
| Total Assets | $747.7M |
| Total Liabilities | $411.9M |
| Equity | $335.8M |
About Zenas Biopharma Inc
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
Zenas Biopharma Inc is a publicly traded company under the ticker symbol ZBIO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
14 analysts (2026-07-01)